ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LY4057996

A development code. Also written as “LY4057996 SC” and “LY4057996 IV”.

Its studies are mostly in Diabetes Mellitus, Type 1, led by Eli Lilly.

Furthest: phase 1, since Apr 18, 20251 company-led study, 1 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Apr 18, 2025Apr 18, 2025Jul 2027phase 1 · NCT06945406

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2025First study: phase 1 study in Diabetes Mellitus, Type 1First studyNCT06945406 · 124 planned · Germany
  2. Sep 29, 2026Primary completion moved from 2026-12 to 2027-03Date moved laterphase 1 · +3 months · NCT06945406
  3. Nov 17, 2026Primary completion moved from 2027-03 to 2027-07Date moved laterphase 1 · +4 months · NCT06945406

Ahead

  1. Jul 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 1NCT06945406

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06945406Diabetes Mellitus, Type 1 · Germany1RecruitingJul 2027124

How it is read

Names in the registry

  • “LY4057996 SC”, 1 entry
  • “LY4057996 IV”, 1 entry

Codes read as this program: LY4057996.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.